Suraksha Diagnostic Ltd (SURAKSHA) — FY26 Annual Report | 27 August 2026

27 August 2026 · BSE 🔴 High Importance Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

🔄 What Changed

Revenue grew to ₹31,041.41 crore (up from ₹25,347.84 crore), PAT increased to ₹3,406.22 crore, EBITDA rose to ₹986 million, and 11 new centers were added to reach 68 total centers. The company also acquired a 63% stake in Fetomat Wellness and launched Genexus platform.

🔮 What's Next

The company plans to add 11 new centers in FY27, expand into Eastern and North-Eastern India, and enhance genomics and AI-driven diagnostics capabilities.

💡 Investor Takeaway

The company is aggressively expanding its diagnostic network and genomics capabilities while maintaining strong profitability, but faces execution risks from geographic concentration and integration of new acquisitions.

Suraksha Diagnostic Limited reported FY2025-26 revenue of ₹31,041.41 crore and PAT of ₹3,406.22 crore, driven by expansion to 68 diagnostic centers and 193 collection points serving 1.37 million patients. The company launched Genexus for rapid oncology testing, acquired a 63% stake in Fetomat Wellness to strengthen fetal medicine, and added 11 new centers in FY27. EBITDA margin improved to 31.8% with [amount context mismatch] million EBITDA. Key risks include geographic concentration in Eastern India, low consultation service contribution (7%), and expansion-related operational pressures. The Board recommended a dividend of [amount context mismatch] per share (25% payout).

📄 View Original Announcement (PDF)

📊 Stock Analysis — SURAKSHA ✨ Ask AI About This

About Suraksha Diagnostic Ltd (SURAKSHA)

Healthcare · Healthcare · Listed on BSE

Market Cap: ₹1,809.55 CrP/E: 50.5ROE: 14.6%ROCE: 16.6%Div Yield: 0.14%

View full SURAKSHA stock details →

📡 Get AI alerts when SURAKSHA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SURAKSHA — Free

💡 Ask AI about this filing

"What is the expected revenue contribution from the 11 new centers planned for FY27?""How will the Fetomat Wellness acquisition impact profitability margins?""What specific risks exist in expanding into North-Eastern India?"

Ask AI Free →

📊 More SURAKSHA filings

Announcement — 28 September 2026Suraksha Diagnostic Limited announced that its trading window will close on 1 October 2026 and remai...
🟡 Voting Results — 24 September 2026Suraksha Diagnostic Limited held its 21st AGM on September 22, 2026 via video conference, approving ...
🟡 Board Meeting — 23 September 2026Suraksha Diagnostic held its 21st AGM on September 22, 2026, approving audited standalone and consol...
🟡 Board Meeting — 22 September 2026Suraksha Diagnostic held its 21st AGM on September 22, 2026, approving audited standalone and consol...
Announcement — 17 August 2026Suraksha Diagnostic reported strong Q1 FY'27 results with 21% revenue growth, 28% EBITDA growth, and...

See all SURAKSHA filings →

🔥 Also filed on 27 August 2026

JNPRJuniper Green Energy LtdFinancial Results AWFISAWFIS Space Solutions LtdAnnual Report 509084Photon Capital Advisors LtdAnnual Report GUJALKALIGujarat Alkalies & Chemicals LtdAnnual Report EPACKEpack Durable LtdAnnual Report 538546Bansal Roofing Products LtdCorporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SURAKSHA files new disclosures

Track SURAKSHA filings, board meetings, and corporate actions. Free email alerts at 5 PM.